In brief
Pharmaceutical companies have reached an agreement to lower the prices of 15 popular prescription drugs for Medicare, which is expected to save billions for both taxpayers and seniors. The new prices will take effect in 2027 as a result of the Medicare drug negotiation program initiated under the Biden administration and continued by the Trump administration. The negotiations span essential medications, including treatments for diabetes, asthma, and various forms of cancer. The initiative aims to provide financial relief to Medicare beneficiaries, with an estimated further cap on out-of-pocket costs set at $2,000. However, challenges remain regarding drug accessibility and pharmaceutical company resistance to government negotiations.
NEW YORK (AP) — In a landmark agreement, pharmaceutical companies have committed to significantly reducing Medicare prices for 15 essential prescription drugs following extensive negotiations. These reductions are projected to generate substantial savings amounting to billions for taxpayers and seniors alike.
However, it is important to note that the announced net prices for a month's supply of these medications might not reflect the final costs Medicare recipients will encounter at their pharmacies, as actual expenses will vary depending on individual plan details and annual prescription expenditures.
Health Secretary Robert F. Kennedy Jr. heralded these agreements as a stride toward addressing affordability concerns for Americans, navigating the implementation of the Medicare drug negotiation program, which was enacted by law during President Joe Biden's tenure.
President Trump urged us to exert all possible efforts to lower healthcare costs for American citizens, Kennedy stated in a Tuesday evening announcement. In our quest to Make America Healthy Again, we will leverage every available resource to provide affordable healthcare for seniors.
The new deal signifies the culmination of a second round of negotiations under a 2022 regulation that allows Medicare to negotiate prices for the most utilized and expensive prescription drugs affecting older Americans. This brings the total to 25 negotiated drugs, with changes set to commence in 2027. The first set of negotiated prices under the Biden administration will come into effect in January.
Negotiated Drug Prices: A Focus on Key Medical Treatments
The latest negotiations encompass crucial medications that traditionally incur high spending from Medicare, including widely-used GLP-1 diabetes and weight-loss drugs such as Ozempic, Rybelsus, and Wegovy. Additional drugs included in this new agreement treat various conditions, such as asthma, psoriatic arthritis, diabetes, and several types of cancer.
Dr. Mehmet Oz, CMS administrator, emphasized that the current administration delivered a substantially improved outcome for taxpayers and seniors in the Medicare Part D program compared to prior negotiations.
The initial negotiations led by the Biden administration were expected to save around $6 billion in net covered prescription drug costs. In comparison, the Trump administration anticipates its recent negotiations could potentially save about $8.5 billion in net spending. Yet, the precise savings for beneficiaries when purchasing drugs remain indefinite due to varying individual circumstances affecting their plans.
An additional rule implemented this year establishes a cap on out-of-pocket costs at $2,000 for Medicare beneficiaries, presenting a financial relief measure for seniors facing expensive prescriptions. Estimated savings from the drug plans for these beneficiaries stand at approximately $685 million.
Spencer Perlman, director of healthcare research at Veda Partners, indicated that these positive outcomes are likely due to an improved selection of drugs for negotiation and lessons learned from the previous round of negotiations.
Despite the efforts to lower the costs of the identified medications, the situation remains unclear regarding the accessibility of GLP-1 drugs for obesity treatment for Medicare beneficiaries, as the program historically excludes coverage for weight-loss remedies. Nonetheless, the administration has recently cooperated with pharmaceutical companies to pilot a program expanding coverage for select obese patients.
Pharmaceutical companies have pushed back against the Medicare drug negotiations stimulated by the Inflation Reduction Act (IRA) of 2022, expressing significant concerns over the implications for medical innovation and research funding.
Next year, Medicare is expected to negotiate prices on an additional 15 drugs, including a variety of physician-administered medications for the first time.
